[肥胖症的药物治疗]

[Drug treatment of obesity].

作者信息

Svendsen Ole Lander, Toubro Søren, Breum Leif, Bruun Jens Meldgaard, Astrup Arne V

机构信息

Astrup H:S Bispebjerg Hospital, Endokrinologisk Sektion, Intern Medicinsk Klinik I, København NV.

出版信息

Ugeskr Laeger. 2006 Jan 9;168(2):163-7.

PMID:16403342

Abstract

Acceptable adverse effects and a clinical relevant weight loss of 3 to 5 kilograms have been found in long-term randomized clinical trials for sibutramine (Reductil) and orlistat (Xenical); these drugs may be prescribed for treatment of obesity for a duration of one and four years, respectively. This also seems to be the case for rimonabant (Acomplia), which is expected to receive approval in 2005 or 2006. However, until data on morbidity and mortality are available from RCTs, there is no absolute indication for prescribing drugs for treatment of obesity.

摘要

在西布曲明（诺美亭）和奥利司他（赛尼可）的长期随机临床试验中，已发现可接受的不良反应以及临床上相关的3至5千克体重减轻；这两种药物分别可开处方用于治疗肥胖症一年和四年。利莫那班（Acomplia）似乎也是如此，预计其将在2005年或2006年获得批准。然而，在随机对照试验得出关于发病率和死亡率的数据之前，没有绝对的指征开处方用药治疗肥胖症。